Cholesterol Lowering and Residual Risk in Diabetes, Type 1

Recruiting now · Phase 4

Conditions studied: Type 1 Diabetes

In brief

This is a prospective, interventional, cohort study, meaning that researchers will follow and observe a group of enrolled study participants over a period of time (one to two months) to gather information and record any developments of the outcomes in question. This study will recruit 125 participants with Type 1 Diabetes (T1D) to: 1. Analyze the effect of reducing the cholesterol levels in the blood on platelet function. (Platelets are small cells in the blood which help form blood clots to slow or stop bleeding and to help wounds heal 2. Analyze the effect of reducing the cholesterol levels in the blood on While Blood Cell (WBC) gene expression, (White Blood Cells are part of the body's immune system which help the body fight infection and other diseases) and 3. Analyze the effect of reducing the cholesterol levels in the blood on vascular or blood vessel function.

Key facts

Study ID

NCT05641753

Run by

NYU Langone Health

People needed

125

Starts

2022-12-06

Expected to finish

2027-07-31

Last updated by the study team

2025-12-29

Who can join

Age: 18 and older, up to 89. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants with previous diagnosis of T1D (as defined by American Diabetes Association or judgment of physician for at least 1 year)
• American Diabetes Association Criteria for diagnosis of diabetes (Must meet at least 1 of the following criteria):
• i. FPG ≥126 mg/dL (7.0 mmol/L). Fasting is defined as no caloric intake for at least 8 hours, OR;
• ii. 2-h PG ≥200 mg/dL (11.1 mmol/L) during OGTT. The test should be performed using a glucose load containing the equivalent of 75 g anhydrous glucose dissolved in water, OR;
• iii. A1C ≥6.5% (48 mmol/mol), OR;
• iv. In a patient with classic symptoms of hyperglycemia or hyperglycemic crisis, a random plasma glucose ≥200 mg/dL (11.1 mmol/L), AND;
• History of T1D (due to autoimmune β-cell destruction, usually leading to absolute insulin deficiency, including latent autoimmune diabetes of adulthood). Autoimmune markers include islet cell autoantibodies and autoantibodies to GAD (glutamic acid decarboxylase, GAD65), insulin, the tyrosine phosphatases islet antigen 2 (IA-2) and IA-2β, and zinc transporter 8, OR;
• Diagnosis of T1D and confirmed by review of records by 2 separate clinical members of the study team
• Age ≥ 18 \& < 90
• LDL-C >100mg/dl
• Able and willing to provide written informed consent for the study

You may not qualify if…

• Established cardiovascular disease on antithrombotic therapy
• Triglycerides >400mg/dl
• Use of a PCSK9 inhibitor
• Recent infection in the past 30 days
• Any hospitalization in the past 30 days
• Use of immunosuppressive therapy
• Use of any antithrombotic therapy
• Use of aspirin
• Use of NSAID within the past 72 hours
• Pregnancy
• Anemia (hemoglobin < 9 g/dl) or thrombocytopenia (platelet count <75), or thrombocytosis (platelet count >600)
• A history of hemorrhagic diathesis
• Chronic kidney disease (CrCl < 30ml/min)
• T2D, monogenic diabetes syndromes, or diabetes in the context of disease of the exocrine pancreas (such as pancreatitis, trauma or pancreatectomy, neoplasia, cystic fibrosis, hemochromatosis)

Where it is running

• New York VA Hospital — New York, New York, United States (enrolling)
• NYC Health + Hospitals/Bellevue — New York, New York, United States (enrolling)
• NYU Langone Health — New York, New York, United States (enrolling)
• Mount Sinai School of Medicine — New York, New York, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.